Solas Capital Management LLC Takes Position in Sanuwave Health Inc. $SNWV

Key Points

• Solas Capital Management LLC invested approximately $20.66 million in Sanuwave Health Inc., acquiring 584,048 shares, making it the institutional investor's second largest position.
• Shares of Sanuwave Health are currently rated as a "buy" by several analysts, with Roth Capital raising the price target from $54.00 to $55.00.
• Sanuwave Health reported $0.01 earnings per share for the last quarter, exceeding the consensus estimate of ($0.09), and had revenue of $10.16 million.

Solas Capital Management LLC bought a new position in shares of Sanuwave Health Inc. (NASDAQ:SNWV - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 584,048 shares of the company's stock, valued at approximately $20,658,000. Sanuwave Health accounts for about 11.6% of Solas Capital Management LLC's holdings, making the stock its 2nd biggest holding. Solas Capital Management LLC owned 6.83% of Sanuwave Health as of its most recent SEC filing.

Separately, Strategic Investment Solutions Inc. IL purchased a new position in shares of Sanuwave Health in the first quarter valued at approximately $47,000. Institutional investors own 42.53% of the company's stock.

Sanuwave Health Trading Down 1.5%

SNWV stock traded down $0.57 during midday trading on Friday, reaching $38.07. 17,694 shares of the company were exchanged, compared to its average volume of 51,238. Sanuwave Health Inc. has a 1-year low of $5.21 and a 1-year high of $46.58. The company's 50-day moving average price is $37.31. The company has a market capitalization of $326.26 million, a P/E ratio of -4.61 and a beta of 1.39.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.10. The company had revenue of $10.16 million for the quarter, compared to analyst estimates of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Wall Street Zen raised shares of Sanuwave Health from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 30th. Northland Capmk raised shares of Sanuwave Health to a "strong-buy" rating in a research note on Wednesday. Northland Securities started coverage on shares of Sanuwave Health in a report on Wednesday. They issued an "outperform" rating and a $55.00 target price on the stock. Finally, Roth Capital raised their target price on shares of Sanuwave Health from $54.00 to $55.00 and gave the company a "buy" rating in a report on Friday, August 22nd. One research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to MarketBeat, Sanuwave Health has an average rating of "Buy" and a consensus target price of $55.00.

Sanuwave Health Company Profile

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.